Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that it has received a purchase order from its Chinese partner Shijiazhuang Yuanjia Biotechnology Co. Ltd. (“Yuanjia Bio”) for 106,000 units of VagiVital® for delivery in two shipments – 53,000 units before the end of the year, and 53,000 units during Q1 2021.
The Products are to be used for a large scale study to collect user experience data to support the registration process in China and for building brand awareness among gynaecologists and gynaecology clinics across the country. The Products will be sold via Yuanjia Bio’s extensive distribution network and on-line via the local VagiVital®webshop (www.vagivital.cn).
– This order is an indication of the high level activity by Yuanjia Bio in support of the marketing authorization application and subsequent full scale launch of VagiVital® , says Dr Johan Inborr, CEO of Peptonic Medical.
The process of obtaining marketing approval for VagiVital® in China is progressing according to plan, and is expected to be completed during the first quarter of 2021.
Through its market research in China, Yuanjia Bio has identified four primary target patient groups for VagiVital®, including e.g. menopausal and post-partum women, with a total number of approximately 415 million women. China’s so called ‘gyneacological inflammatory market’ was estimated to reach 26.9 billion yuan (approx. 3.5 billion Euro) in sales in 2018. Between 2013 and 2017, this market grew at a rate of 7.6 percent annually.
For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
E-mail: johan.inborr@peptonicmedical.se
This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14th August, 2020.
About VagiVital®
VagiVital® is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.
VagiVital® was launched in Sweden as a non-prescription self-care product in July 2018 (see www.vagivital.com).
About Peptonic Medical
Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.
VagiVital® is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.
Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (www.spotlightstockmarket.se, ticker: PMED) in Stockholm, Sweden.
For more information: www.peptonicmedical.com
